CMA again accuses Advanz of pharma collusion
The UK’s competition watchdog has issued a fourth statement of objections against Advanz Pharma, now accusing the drugmaker and two others of carving up the market for the antibiotic Nitrofurantoin.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.